Novel Quadrilateral Surface Plate for Acetabular Fracture
Launched by HEBEI MEDICAL UNIVERSITY THIRD HOSPITAL · Jan 18, 2017
Trial Information
Current as of August 19, 2025
Unknown status
Keywords
ClinConnect Summary
Stoppa approach was more minimally invasive than ilioinguinal approach for pelvic and acetabular fractures. Then, Stoppa approach was widely used clinically. For the fragments involving quadrilateral surface, the Kocher-Langenbeck approach was added because the fixation of posterior fragments could not be obtained with reconstruction plate through single Stoppa approach. Novel quadrilateral surface plate was used in this study to examine its fixed role for posterior fragments. Functional outcome and complication were recorded to compare with the results treated with reconstruction plate. If...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Over 18 years old
- • Fracture involving quadrilateral surface
- • Operation was conducted within 14 days
- • Fixed with quadrilateral surface plate through Stoppa approach
- Exclusion Criteria:
- • Presented with a pathologic acetabular fracture
- • Neuropathic arthropathy,dementia and other disease processes which made postoperative compliance unreliable
- • Refused to participate
- • Follow-up insufficient 12 months
About Hebei Medical University Third Hospital
Hebei Medical University Third Hospital is a leading healthcare institution dedicated to advancing medical research and improving patient care. As a prominent clinical trial sponsor, the hospital focuses on innovative therapies and evidence-based practices across various medical fields. With a commitment to ethical standards and patient safety, the institution collaborates with multidisciplinary teams to conduct rigorous clinical studies that contribute to the scientific community and enhance treatment options. Leveraging state-of-the-art facilities and a patient-centric approach, Hebei Medical University Third Hospital plays a vital role in the advancement of clinical research and the development of new healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shijiazhuang, Hebei, China
Patients applied
Trial Officials
Ruipeng Zhang, M.D
Principal Investigator
Third Hospital of Hebei Medical University Department of Orthopaedic Surgery
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials